| Bioactivity | Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD[1]. |
| Name | Pegsebrenatide |
| CAS | 2243292-26-2 |
| Formula | C₂₀₆H₃₁₈N₅₄O₆₉S₂(C₂H₄O)m+₂n; m≈₁₀; n≈₂₀ |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jacob K Sterling, et al.GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension. Cell Rep. 2020, 33, 5. |
Pegsebrenatide
CAS: 2243292-26-2 F: C₂₀₆H₃₁₈N₅₄O₆₉S₂(C₂H₄O)m+₂n; m≈₁₀; n≈₂₀ W:
Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-bra
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.